Completed PHASE1 INTERVENTIONAL 4-arm NCT01905410

Phase I Study to Investigate Safety, Tolerability, and Pharmacokinetics of VVZ-149 Injection (P1_VVZ149IV)

A Randomized, Double-blind, Single and Multiple Ascending Dose Escalation, Placebo-controlled Clinical Trial to Investigate Safety, Tolerability, and Pharmacokinetics of VVZ-149 Injection in Healthy Male Volunteers

Sponsor: Vivozon, Inc.

Conditions Healthy

Interventions VVZ-149 Injection placebo

Updated 7 times since 2017 Last updated: Mar 11, 2019 Started: Jul 31, 2013 Primary completion: Mar 31, 2014 Completion: Apr 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01905410, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Vivozon, Inc., it has been updated 7 times since 2013, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Apr 2019 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Jun 2018 — Apr 2019 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Jul 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vivozon, Inc.

Data source: Vivozon, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Sungnam-Si, South Korea